Effects of eight weeks exercise training on serum levels of adropin in male volleyball players

Afşin, Abdülmecit; Bozyılan, Eren; Asoğlu, Ramazan; Yavuz, Fethi; Dündar, Aykut

doi:10.1515/hmbci-2020-0094

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In professional soccer players, adropin concentrations did not change throughout the year, regardless of whether they were in pre-season or in-season (167). Meanwhile, in young, healthy, male volleyball players, eight weeks of a combination of aerobic, plyometric, and resistance training increased adropin (168). Following six weeks of swimming, rats demonstrated an increase in hepatic and pancreatic Enho mRNA expression, however, no circulating adropin concentrations were reported (169).…”

Section: Exercise and Adropinmentioning

confidence: 86%

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Jurrissen

Ramirez‐Perez

Cabral-Amador

et al. 2022

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Adropin is a peptide largely secreted by the liver and known to regulate energy homeostasis; however, it also exerts cardiovascular effects. Herein, we tested the hypothesis that low circulating levels of adropin in obesity and type 2 diabetes (T2D) contribute to arterial stiffening. In support of this hypothesis, we report that obesity and T2D is associated with reduced levels of adropin (in liver and plasma) and increased arterial stiffness in mice and humans. Establishing causation, we show that mesenteric arteries from adropin knockout mice are also stiffer, relative to arteries from wild-type counterparts, thus recapitulating the stiffening phenotype observed in T2D db/db mice. Given the above, we performed a set of follow-up experiments, in which we found that: 1) exposure of endothelial cells or isolated mesenteric arteries from db/db mice to adropin reduces filamentous actin (F-actin) stress fibers and stiffness; 2) adropin-induced reduction of F-actin and stiffness in endothelial cells and db/db mesenteric arteries is abrogated by inhibition of nitric oxide (NO) synthase; and 3) stimulation of smooth muscle cells or db/db mesenteric arteries with a NO mimetic reduces stiffness. Last, we demonstrated that in vivo treatment of db/db mice with adropin for four weeks reduces stiffness in mesenteric arteries. Collectively, these findings indicate that adropin can regulate arterial stiffness, likely via endothelial-derived NO, and thus support the notion that "hypoadropinemia" should be considered as a putative target for the prevention and treatment of arterial stiffening in obesity and T2D.

show abstract

Section: Exercise and Adropinmentioning

confidence: 86%

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Jurrissen

Ramirez‐Perez

Cabral-Amador

et al. 2022

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

Advances in Research on Adropin: Potential Implications for Clinical Diagnosis and Possible Treatment – A Mini-Review

Berdowska,

Berdowska

2024

View full text Add to dashboard Cite

Adropin is 76-amino acids protein. It was discovered in 2008. Adropin expression was found in the liver, brain, heart, kidneys, pancreas, testis and ovary, umbilical vein, coronary artery endothelial cells, aortic smooth muscle cells and monocytes/macrophages. Adropin is involved in energy balance, and it has an endothelial protective effect. Changes in adropin content have been found in many diseases and disorders, such as obesity, diabetes mellitus type 1 and 2, coronary artery disease, myocardial infarction, rheumatoid arthritis, primary Sjögren's syndrome, multiple sclerosis, nonalcoholic fatty liver disease, polycystic ovary syndrome and preeclampsia. This mini-review focuses on those papers that have potential implications for clinical diagnosis or possible treatment.It can be assumed that adropin can be useful in the diagnosis of certain diseases. It seems to be a promising candidate for the treatment of diabetes, atherosclerosis, polycystic ovary syndrome and diseases of the nervous system associated with cognitive decline.

show abstract

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Jurrissen¹

View full text Add to dashboard Cite

Adropin is a peptide largely secreted by the liver and known to regulate energy homeostasis; however, it also exerts cardiovascular effects. Herein, I tested the hypothesis that low circulating levels of adropin in obesity and type 2 diabetes (T2D) contribute to arterial stiffening. In support of this hypothesis, I report that obesity and T2D is associated with reduced levels of adropin expression in liver and plasma and increased arterial stiffness in mice and humans. Establishing causation, I showed that mesenteric arteries from adropin knockout mice are also stiffer relative to arteries from wild-type counterparts, thus recapitulating the stiffening phenotype observed in T2D db/db mice. Given the above, a series of follow-up experiments were performed that determined: 1) exposure of endothelial cells or isolated mesenteric arteries from db/db mice to adropin reduces filamentous actin (F-actin) stress fibers and stiffness; 2) adropininduced reduction of F-actin and stiffness in endothelial cells and db/db mesenteric arteries is abrogated by inhibition of nitric oxide (NO) synthase; and 3) stimulation of smooth muscle cells or db/db mesenteric arteries with a NO mimetic reduces stiffness. Last, in vivo treatment of db/db mice with adropin for four weeks reduced stiffness in mesenteric arteries. Collectively, these findings indicate that adropin can regulate arterial stiffness, likely via endothelial-derived NO, and thus support the notion that "hypoadropinemia" should be considered as a putative target for the prevention and treatment of arterial stiffening in obesity and T2D.

show abstract

Effects of eight weeks exercise training on serum levels of adropin in male volleyball players

Cited by 3 publications

References 34 publications

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Advances in Research on Adropin: Potential Implications for Clinical Diagnosis and Possible Treatment – A Mini-Review

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Contact Info

Product

Resources

About